



August 6, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact: Masaya Saito, Vice President and CFO

Telephone: +81-6-6758-8223

Notice of Revision of Earnings Forecast

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on May 13, 2026, as described below. The forecast indicated below is also disclosed in the “Consolidated Financial Results for the Three Months Ended March 31, 2027 [Japanese GAAP].”

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A) (Announced on May 13, 2026)	369,500	43,800	46,100	34,500	152.68
Revised forecast (B)	372,300	45,000	47,400	35,200	155.78
Change (B-A)	2,800	1,200	1,300	700	
Percentage change (%)	0.8	2.7	2.8	2.0	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2026)	343,725	41,118	47,971	34,247	151.56

(2) Reasons for the revisions

The Company has revised the consolidated financial earnings forecast announced on May 13, 2026 to reflect a revision to the assumed exchange rates from 155 yen to 158 yen to the US dollar and from 22 yen to 23 yen to the Chinese yuan, as well as favorable performance of the Asia, Japan, and Europe segments, which exceeded expectations during the first quarter of the current fiscal year. Net sales, operating income, ordinary income and profit attributable to owners of parent are all expected to exceed the previous forecast. Net sales are also expected to increase compared to the previous fiscal year, with operating income and profit attributable to owners of parent also expected to increase.

*The above forecasts are based on information available as of the date of announcement. Actual results may differ from the forecasts due to various factors.

Rohto Pharmaceutical Co., Ltd.